On March 27, President Trump signed into law the Coronavirus Aid, Relief, and Economic Security (CARES) Act, which provided more than $2 trillion to support workers, businesses, states, and localities hit by the unprecedented financial impacts of the suddenly essential closure of the economy. The law provided $3.5 billion to BARDA to provide biopharmaceutical companies with funds for the development and manufacturing of vaccines, diagnostics, and treatments, and for the purchase of these products. We volunteered to help expedite our member companies’ access to these funds.
